Health
Source: Bloomberg
Novavax Inc's Covid-19 vaccine has received the emergency-use authorisation from the Drugs and Controller General of India (DCGI) for children aged between 12-17 years.
The vaccine is made and marketed in India by the Serum Institute of India (SII) under the brand name Covovax.
In a last-stage trial involving 2247 teenagers aged 12-17, the vaccine proved out to be 80 per cent effective against Covid-19, Reuters reports.
The vaccine shot has evoked an immune response in the same age group in a late-stage study that involved 460 Indian adolescents.
So far, Biological E's Corbevax, Bharat Biotech's Covaxin and the ZyCov-D of Zydus Cadila have received the DCGI approval to be authorised to adolescents aged 12 and above.
Just last week, children aged between 12-14 started getting the Corbevax vaccine in the country.
Prior to this, the shots were only being given to 15-year-olds and above.
The SII-made Covovax had obtained the DCGI permission to be authorised to adults back in December 2021.
In February, India achieved the milestone of administering 175 crore vaccine doses. The inoculation drive is now being expanded to the young children of the country.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest